Compare AstraZeneca plc (AZN) vs PubMatic Inc (PUBM) Price & Performance

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

PubMatic (PUBM) trades at $17.76, down slightly by 0.11% today. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Recent Q2 2026 earnings beat expectations with 10.5% revenue growth and a significant EPS surprise. The company is focusing on high-margin segments like mobile app and CTV advertising, supported by new AI product launches and executive appointments.

The outlook is cautiously optimistic with a consensus price target of $20.83, implying 17% upside. However, risks include persistent net losses, a high P/E ratio of 132, and competitive pressures in digital advertising. Analyst sentiment is split evenly between Buy and Hold ratings, reflecting uncertainty around near-term profitability.